Skip to main content
Premium Trial:

Request an Annual Quote

CambridgeSoft Raises $21M, Names New VP

NEW YORK (GenomeWeb News) – Life science informatics developer CambridgeSoft said today that it has completed a $21 million private equity investment by Goldman Sachs.
In connection with the offering, Raheel Zia, a vice president at Goldman Sachs Principal Investment Area, will join CambridgeSoft's board of directors.
In addition, CambridgeSoft said that it has hired Michael Stapleton as vice president of corporate development, “with responsibilities for supporting the company's merger and acquisitions activities.”
Stapleton previously served as chief operating officer at Accelrys, where he was responsible for integrating Molecular Simulations, Synopsys, Oxford Molecular Group, and Genetics Computer Group under the Accelrys umbrella.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more